Overview

A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients

Status:
Completed

Trial end date:
2016-11-01

Target enrollment:

Participant gender:

Summary

A clinical study of lurbinectedin(PM01183) alone or in combination with gemcitabine in comparison to docetaxel for the treatment of unresectable non-small cell lung cancer (NSCLC)patients

Phase:

Phase 2

Details

Lead Sponsor:

PharmaMar

Treatments:

Docetaxel
Gemcitabine